Suboxone is the best-known brand of buprenorphine and naloxone, a combination medication approved by the FDA for medication-assisted treatment (MAT) of opioid use disorder. Buprenorphine is a partial opioid agonist that reduces cravings and withdrawal symptoms, while naloxone is added to discourage injection misuse. Indivior manufactures brand Suboxone, Sublocade (a once-monthly injection), and holds the original patent; Orexo makes Zubsolv and other manufacturers make Bunavail. Subutex, the original buprenorphine-only tablet, was discontinued as a branded product but remains available generically and is still used during induction, particularly in pregnancy. Generic buprenorphine/naloxone sublingual film and tablets have been FDA-approved and commercially available since June 2018, when Mylan and Dr. Reddy's Laboratories launched the first generics, followed by Alvogen and additional manufacturers.
Congress passed the Mainstreaming Addiction Treatment Act as part of the Consolidated Appropriations Act of 2023, signed December 29, 2022, eliminating the DEA X-waiver that once required a special federal registration and patient caps to prescribe buprenorphine. Since January 2023, any practitioner with a standard DEA registration can prescribe buprenorphine for opioid use disorder, subject to state law, which has expanded access at pharmacies nationwide. Cash prices in 2026 still vary widely: generic buprenorphine/naloxone film averages about $113 per month without a coupon and drops to $30 to $65 with a GoodRx or manufacturer discount card, while brand-name Suboxone averages $534 to $650 per month. Patients weighing whether to fill at retail cash price should first check whether their income qualifies them for reduced-cost coverage through Medicaid income limits before paying out of pocket.
The federal SUPPORT for Patients and Communities Act of 2018 requires every state Medicaid program, including managed care plans, to cover at least one form of FDA-approved buprenorphine for opioid use disorder. That mandate does not ban prior authorization, so roughly half of states still require it before covering buprenorphine, which is a common source of treatment delay. Medicare covers buprenorphine two ways: through Part D for the sublingual film and tablets patients pick up at a retail pharmacy, and through Part B's bundled opioid treatment program (OTP) benefit for patients who receive medication and counseling at a certified opioid treatment program, with $0 beneficiary cost-sharing for OTP services. Patients unsure whether they qualify for low-cost Medicaid or Medicare coverage should review Medicare eligibility rules alongside their state's Medicaid income limits.
What Suboxone Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same suboxone can cost many times more at a hospital than at your local pharmacy:
2026 Suboxone Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Pharmacy counter (generic film/tablet, cash) | $65 - $250/month | Full cash price without insurance or coupon for generic buprenorphine/naloxone in 2026; lower with GoodRx or a manufacturer coupon |
| Pharmacy counter (brand Suboxone, cash) | $500 - $650/month | Brand-name list price without insurance in 2026; the Uninsured Savings Card can lower this by up to $170/month |
| Medicare Part D (2026) | $0 - $45/month, capped at $2,100/year | Formulary tier and prior authorization requirements vary by plan; Extra Help enrollees pay a reduced flat copay |
| Medicaid | $0 - $4/prescription | Covered in all 50 states under the federal SUPPORT Act; about half of states still require prior authorization |
| Suboxone INSUPPORT copay card (commercial insurance) | As little as $5/month; saves up to $75/fill | For commercially or privately insured patients only; not valid with Medicare, Medicaid, TRICARE, or VA |
Retail prices reflect 2026 GoodRx, SingleCare, and Kroger Health Savings data. Part D ranges depend on your plan's formulary tier and where you are in your benefit year. Sublocade, the extended-release injection, is billed separately under Medicare Part B; see the HCPCS section below.
Source: CMS Part D 2026 benefit design, suboxone.com savings programs, GoodRx, Kroger Health Savings
Why Hospitals Charge So Much
Emergency departments increasingly start buprenorphine induction on-site for patients presenting in opioid withdrawal, a practice supported by SAMHSA and CDC guidance to reduce overdose risk during the wait for outpatient treatment. When that happens, the drug charge itself is usually small (a few sublingual films cost only a few dollars at acquisition cost), but hospitals frequently bundle a facility fee, an emergency severity level charge, and observation charges around the induction visit. Patients who see a bill of $800 or more for a single ED buprenorphine induction should ask for an itemized statement and compare the drug line item against the facility fee separately.
Residential and outpatient addiction treatment programs bill buprenorphine differently depending on whether the patient is enrolled at a certified opioid treatment program (OTP) or a standard outpatient practice. OTPs bill Medicare Part B using a bundled weekly or monthly payment that covers the medication, counseling, and toxicology testing together, with $0 beneficiary cost-sharing for many services. Standard outpatient prescribers instead send the prescription to a retail pharmacy, which bills separately through Part D or Medicaid. Patients transitioning between these settings should confirm which billing pathway applies to avoid being charged twice for the same month of medication.
HCPCS J-Codes: What Appears on Your Bill
Sublocade, the once-monthly extended-release buprenorphine injection, is administered in a clinic and billed under Medicare Part B using HCPCS Level II Q-codes rather than through Part D. These codes do not apply to Suboxone sublingual film or tablets, which patients self-administer and which bill through Part D.
HCPCS J-codes for Suboxone| Code | Description | What to look for |
|---|
| Q9992 | Buprenorphine extended-release (Sublocade), greater than 100 mg, for subcutaneous injection | Used for the two initial 300 mg induction doses; confirm this code, not a duplicate office-visit charge, appears on your Part B claim |
| Q9991 | Buprenorphine extended-release (Sublocade), less than or equal to 100 mg, for subcutaneous injection | Used for maintenance dosing after induction; verify your clinic billed the code matching your actual dose |
Sublocade's 2026 list price is approximately $2,202 per monthly dose. Under Medicare Part B, beneficiaries owe 20% coinsurance after the annual Part B deductible, but many patients with Medigap or dual Medicare-Medicaid coverage pay close to $0 out of pocket per dose.
Source: CMS HCPCS Level II Code Set 2026; sublocade.com program materials
Patient Assistance Programs
Indivior, the manufacturer of Suboxone and Sublocade, runs three separate cost-reduction pathways depending on your insurance status. Commercially insured patients use the INSUPPORT copay card; uninsured patients without any prescription coverage can use the Uninsured Savings Card or apply for the free income-based patient assistance program.
Patient assistance programs for Suboxone| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Suboxone INSUPPORT Copay Assistance Program | As little as $5/month copay for commercially insured patients; saves up to $75/month; new patients may receive the first two fills free | suboxone.com/insupport |
| Suboxone Uninsured Savings Card | Up to $170/month off cash price for patients without any prescription drug coverage, applied per film based on strength | suboxone.com |
| Indivior Patient Assistance Program (free Suboxone) | Free brand Suboxone for uninsured patients with an opioid use disorder diagnosis and household income at or below approximately 250% of the federal poverty level | needymeds.org |
| NeedyMeds Drug Discount Card | Variable discount accepted at most US pharmacies for generic buprenorphine/naloxone | needymeds.org |
Manufacturer copay cards, including the INSUPPORT program and the Uninsured Savings Card, cannot legally be used by anyone with Medicare, Medicaid, TRICARE, or VA coverage under the federal anti-kickback statute (42 U.S.C. Section 1320a-7b). If you have government insurance, use Medicaid's $0 to $4 copay, Medicare Part D Extra Help, or the income-based Indivior Patient Assistance Program instead.
Source: suboxone.com INSUPPORT and savings card program pages; NeedyMeds.org patient assistance database
Medicare Part D
Buprenorphine and naloxone sublingual film and tablets are Medicare Part D drugs when a patient picks them up at a retail pharmacy. There is no drug-specific monthly cap for buprenorphine the way there is for insulin. Instead, all out-of-pocket spending on buprenorphine counts toward the standard 2026 Part D annual out-of-pocket cap of $2,100; once you reach that amount for the calendar year across all your Part D drugs, you pay $0 for the rest of the year.
Medicare Part B separately covers medication and counseling delivered through a certified opioid treatment program (OTP), a benefit CMS established in 2020. OTP services, including buprenorphine, methadone, toxicology testing, and counseling, are billed as a bundled weekly or monthly payment, and CMS has set beneficiary cost-sharing at $0 for many of these services, removing a major access barrier for patients receiving care at an OTP rather than a standard outpatient prescriber.
Sublocade, the once-monthly injection, does not run through Part D at all. It falls under Part B when administered in a clinic, where beneficiaries owe 20% coinsurance after the 2026 Part B deductible of $283, though supplemental coverage often reduces that to near $0.
Common Suboxone Billing Errors
Buprenorphine billing errors cluster around prior authorization, generic substitution, and confusion between the Part D pharmacy pathway and the Part B/OTP pathway. Check for these issues before paying a bill above the ranges listed in the point-of-pay table:
- Medicaid charging more than the state's standard $0 to $4 copay for buprenorphine, which may violate your state's cost-sharing policy for opioid use disorder medications under the SUPPORT Act mandate.
- Brand-name Suboxone dispensed and billed when a generic buprenorphine/naloxone equivalent was in stock and would have cost several hundred dollars less per month.
- Prior authorization required for buprenorphine despite your state Medicaid program's published policy prohibiting it; call your state Medicaid office to confirm the current rule.
- Emergency department buprenorphine induction billed as a large separate pharmacy line item instead of being bundled into the standard facility and physician charges for the visit.
- INSUPPORT copay card or Uninsured Savings Card applied to a Medicare or Medicaid claim, which triggers a rejection under the federal anti-kickback statute and can delay your fill.
- Sublocade billed as a retail pharmacy prescription claim instead of a Medicare Part B medical claim using Q9991 or Q9992, which typically results in denial since Part D plans generally do not cover Sublocade.
Frequently Asked Questions
Is there a generic for Suboxone?
Yes. Generic buprenorphine/naloxone sublingual film has been FDA-approved and commercially available since June 14, 2018, when Mylan Technologies and Dr. Reddy's Laboratories launched the first versions. Alvogen and other manufacturers followed in 2019. Generic cash prices in 2026 run $30 to $250 per month, compared to $500 to $650 for brand-name Suboxone. Buprenorphine is a small-molecule drug, not a biologic, so it has generics rather than biosimilars. Sublocade, the extended-release monthly injection, does not yet have a generic equivalent.
How do I apply for the Indivior Suboxone patient assistance program?
Visit suboxone.com or call 1-877-678-7493 to request a patient assistance program application. Ask your prescriber to complete the prescriber attestation section confirming your opioid use disorder diagnosis. Gather proof of income, such as a recent federal tax return or two pay stubs, and confirm you have no other prescription drug coverage. Submit the completed application by fax or mail as instructed; processing typically takes 1 to 3 weeks. If approved, free Suboxone ships directly to you or your prescriber's office, and you generally reapply annually.
Can I use the Suboxone INSUPPORT savings card with Medicare?
No. Federal anti-kickback law prohibits manufacturer copay cards, including the INSUPPORT program and the Uninsured Savings Card, from being used by anyone with Medicare, Medicaid, TRICARE, or VA coverage. The INSUPPORT card is for commercially insured patients only and caps their copay near $5 per month. Medicare beneficiaries should instead ask about Part D Extra Help, which reduces copays for low-income enrollees, or apply for Indivior's income-based patient assistance program if uninsured.
What if my insurance denies coverage or requires prior authorization for buprenorphine?
Request the written denial notice from your plan, then file a formal appeal within the plan's deadline, which is generally 60 days for Medicare Part D. Ask your prescriber to submit a peer-to-peer review citing SAMHSA and CDC guidance that prior authorization delays for opioid use disorder medications increase overdose risk. Roughly half of states prohibit Medicaid prior authorization for buprenorphine outright, so confirm your state's current policy. If denied again, escalate to an external review through your state insurance department or the Medicare Part D appeals process.
Does the IRA negotiated price apply to Suboxone or buprenorphine?
No. Buprenorphine and naloxone are not among the drugs selected for Medicare's Inflation Reduction Act price negotiation program, so there is no Maximum Fair Price for Suboxone in 2026. Instead, Medicare Part D patients pay their plan's standard formulary tier cost, and all spending counts toward the general 2026 annual Part D out-of-pocket cap of $2,100, the same cap that applies to most non-negotiated Part D drugs.
What does Suboxone cost without insurance at the pharmacy counter in 2026?
Generic buprenorphine/naloxone film costs $65 to $250 per month in cash, with the lowest verified prices around $30 to $45 using a GoodRx coupon at Walgreens or CVS. Brand-name Suboxone costs $500 to $650 per month without insurance. Buprenorphine is a Schedule III controlled substance, so it is excluded from Walmart's flat $4 Generic Prescription Program, though standard discount coupons are still accepted.
Do I qualify for the Indivior patient assistance program?
Eligibility generally requires an opioid use disorder diagnosis, no prescription drug coverage, and household income at or below approximately 250% of the federal poverty level, which is $39,900 for a household of one and $82,500 for a household of four in 2026. Applicants must also provide proof of US residency and a valid buprenorphine prescription. Common denial reasons include income above the threshold, having other coverage that includes buprenorphine, or an incomplete application missing the prescriber's signature.
What is the difference between Suboxone, Sublocade, Subutex, and generic buprenorphine/naloxone?
Suboxone and generic buprenorphine/naloxone are both sublingual films or tablets containing buprenorphine plus naloxone, taken daily; the generic costs far less. Subutex was the original buprenorphine-only tablet without naloxone, now discontinued as a brand but still made generically and used mainly during induction or in pregnancy. Sublocade is a different formulation entirely: a once-monthly extended-release injection administered in a clinic and billed under Medicare Part B rather than Part D, with a 2026 list price near $2,202 per dose.
